Genfit's assay will be deployed through Covance's central laboratories to validate its use to better identify and characterize patients with the liver disease.
The Massachusetts Institute of Technology spinout has created a new class of activity sensors that query the body and report back clinically relevant information.
Glycotest's biomarker test for detection of hepatocellular carcinoma calculates the amount of monosaccharide fucose that appears abnormally on specific serum glycoproteins.
Factors that may have led to the explosion in testing include more consultations between patients and general practitioners, and a fear among GPs of being sued.
The funding will be directed at conducting clinical trials for its technology based on activity sensors to detect human diseases and monitor drug responses.
The platform, which its developers said is well suited to point-of-care testing, uses fluorescent polymers to distinguish between samples from cases and controls.
